Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice

Overview

Journal CNS Neurol Disord Drug Targets

Publisher Bentham Science Publishers

Specialties Neurology
Pharmacology

Date 2009 Mar 12

PMID 19275636

Citations 49

Authors

Donna M Wilcock

Carol A Colton

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a progressive, neurodegenerative disorder that results in severe cognitive decline. Amyloid plaques are a principal pathology found in AD and are composed of aggregated amyloid-beta (Abeta) peptides. According to the amyloid hypothesis, Abeta peptides initiate the other pathologies characteristic for AD including cognitive deficits. Immunotherapy against Abeta is a potential therapeutic for the treatment of humans with AD. While anti-Abeta immunotherapy has been shown to reduce amyloid burden in both mouse models and in humans, immunotherapy also exacerbates vascular pathologies. Cerebral amyloid angiopathy (CAA), that is, the accumulation of amyloid in the cerebrovasculature, is increased with immunotherapy in humans with AD and in mouse models of amyloid deposition. CAA persists in the brains of clinical trial patients that show removal of parenchymal amyloid. Mouse model studies also show that immunotherapy results in multiple small bleeds in the brain, termed microhemorrhages. The neurovascular unit is a term used to describe the cerebrovasculature and its associated cells-astrocytes, neurons, pericytes and microglia. CAA affects brain perfusion and there is now evidence that the neurovascular unit is affected in AD when CAA is present. Understanding the type of damage to the neurovascular unit caused by CAA in AD and the underlying cause of microhemorrhage after immunotherapy is essential to the success of therapeutic vaccines as a treatment for AD.

Citing Articles

Exposure to Lead in Drinking Water Causes Cognitive Impairment via an Alzheimer's Disease Gene-Dependent Mechanism in Adult Mice.

Kohler K, Macheda T, Hobbs M, Maisel M, Rodriguez A, Farris L J Alzheimers Dis. 2024; 100(s1):S291-S304.

PMID: 39121129 PMC: 11616619. DOI: 10.3233/JAD-240640.

Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier.

Pardridge W Front Drug Deliv. 2023; 3.

PMID: 37583474 PMC: 10426772. DOI: 10.3389/fddev.2023.1227816.

IgG Fusion Proteins for Brain Delivery of Biologics via Blood-Brain Barrier Receptor-Mediated Transport.

Boado R Pharmaceutics. 2022; 14(7).

PMID: 35890374 PMC: 9322584. DOI: 10.3390/pharmaceutics14071476.

Contrasting Metabolic Insufficiency in Aging and Dementia.

Turner D Aging Dis. 2021; 12(4):1081-1096.

PMID: 34221551 PMC: 8219502. DOI: 10.14336/AD.2021.0104.

Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer's disease pathology in aged squirrel monkeys.

Patel A, Nehete P, Krivoshik S, Pei X, Cho E, Nehete B Brain. 2021; 144(7):2146-2165.

PMID: 34128045 PMC: 8502485. DOI: 10.1093/brain/awab129.

References

Skatchkov S, Eaton M, Shuba Y, Kucheryavykh Y, Derst C, Veh R . Tandem-pore domain potassium channels are functionally expressed in retinal (Müller) glial cells. Glia. 2005; 53(3):266-76. DOI: 10.1002/glia.20280. View

Iadecola C, Nedergaard M . Glial regulation of the cerebral microvasculature. Nat Neurosci. 2007; 10(11):1369-76. DOI: 10.1038/nn2003. View

Janus C, Pearson J, McLaurin J, Mathews P, Jiang Y, Schmidt S . A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2001; 408(6815):979-82. DOI: 10.1038/35050110. View

Wallraff A, Kohling R, Heinemann U, Theis M, Willecke K, Steinhauser C . The impact of astrocytic gap junctional coupling on potassium buffering in the hippocampus. J Neurosci. 2006; 26(20):5438-47. PMC: 6675300. DOI: 10.1523/JNEUROSCI.0037-06.2006. View

Kramer J, Reed B, Mungas D, Weiner M, Chui H . Executive dysfunction in subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry. 2002; 72(2):217-20. PMC: 1737728. DOI: 10.1136/jnnp.72.2.217. View

Folino A . Cerebral autoregulation and syncope. Prog Cardiovasc Dis. 2007; 50(1):49-80. DOI: 10.1016/j.pcad.2007.01.001. View

Abbott N . Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat. 2002; 200(6):629-38. PMC: 1570746. DOI: 10.1046/j.1469-7580.2002.00064.x. View

Lemere C, Spooner E, LaFrancois J, Malester B, Mori C, Leverone J . Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis. 2003; 14(1):10-8. DOI: 10.1016/s0969-9961(03)00044-5. View

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T . Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999; 400(6740):173-7. DOI: 10.1038/22124. View

10.

Bacskai B, Kajdasz S, Christie R, Carter C, Games D, Seubert P . Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med. 2001; 7(3):369-72. DOI: 10.1038/85525. View

11.

van der Werf Y, Scheltens P, Lindeboom J, Witter M, Uylings H, Jolles J . Deficits of memory, executive functioning and attention following infarction in the thalamus; a study of 22 cases with localised lesions. Neuropsychologia. 2003; 41(10):1330-44. DOI: 10.1016/s0028-3932(03)00059-9. View

12.

Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T . Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci. 2008; 28(27):6787-93. PMC: 6670967. DOI: 10.1523/JNEUROSCI.2377-07.2008. View

13.

Wilcock D, Rojiani A, Rosenthal A, Subbarao S, Freeman M, Gordon M . Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004; 1(1):24. PMC: 539292. DOI: 10.1186/1742-2094-1-24. View

14.

Wallraff A, Odermatt B, Willecke K, Steinhauser C . Distinct types of astroglial cells in the hippocampus differ in gap junction coupling. Glia. 2004; 48(1):36-43. DOI: 10.1002/glia.20040. View

15.

Preston S, Steart P, Wilkinson A, Nicoll J, Weller R . Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol. 2003; 29(2):106-17. DOI: 10.1046/j.1365-2990.2003.00424.x. View

16.

Takano T, Han X, Deane R, Zlokovic B, Nedergaard M . Two-photon imaging of astrocytic Ca2+ signaling and the microvasculature in experimental mice models of Alzheimer's disease. Ann N Y Acad Sci. 2007; 1097:40-50. DOI: 10.1196/annals.1379.004. View

17.

Zlokovic B . Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005; 28(4):202-8. DOI: 10.1016/j.tins.2005.02.001. View

18.

Bacskai B, Kajdasz S, McLellan M, Games D, Seubert P, Schenk D . Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci. 2002; 22(18):7873-8. PMC: 6758112. View

19.

Warkentin S, Passant U . Functional imaging of the frontal lobes in organic dementia. Regional cerebral blood flow findings in normals, in patients with frontotemporal dementia and in patients with Alzheimer's disease, performing a word fluency test. Dement Geriatr Cogn Disord. 1997; 8(2):105-9. DOI: 10.1159/000106614. View

20.

Baltuch G . Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci. 1999; 22:219-40. DOI: 10.1146/annurev.neuro.22.1.219. View